*Sponsored by Winning Media |
|
Hey Folks, Jeff Bishop here again — and happy Monday! |
As I mentioned last night, there are some unbelievable opportunities in the market right now, especially in the small-cap sector. |
Just last week, I helped you identify some stocks that made terrific gains in a very short period of time. |
Those prices didn't jump because the company suddenly changed its business model or developed a cure for some disease. |
Rather, they rallied because they were selling at such depressed levels that it was literally stupid for them to stay there much longer. |
Today, I have another idea that I think is "stupid" to see it trading where it is right now, and sometimes you just gotta say – enough is enough. |
If you care at all about small stocks forgotten in the "bargain basement," then you need to look this one up immediately: |
Avalon GloboCare Corp (Nasdaq: ALBT) |
Top of the list should be the fact that just this morning, ALBT announced a key patent filed with one of the most prestigious universities in the world – Massachusetts Institute of Technology (MIT). |
If you have been following the ABLT story like I have, you know this is going to have considerable implications for the company. |
This patented technology could be a huge upside driver for ALBT as they grow their lab testing services. |
But why else should you care about a little stock trading for under $1 right now? |
Great question. |
For starters, consider that ALBT traded over 75% higher than its current price just a few weeks ago. |
Has anything materially changed about the company since then to cause this decline? |
The only news I see is about the company expanding its services into new states and the launch of a new product. |
ALBT announced its earnings on August 14th, and the stock shot up in the days following. Then, on super light volume, the stock drifted lower once again. |
If you ask me, this makes no sense at all. It reminds me of the typical market maker games that get played in the doldrums of summer when all the buyers are on vacation. |
Get this... |
Right now, ALBT is sporting a measly market cap of around $10M (according to Yahoo!), yet over the last few months, it has developed into a premier genetic testing lab that generated $14.7M in sales in 2022 with $8M in gross profit! |
Does that sound like a value play to you?! |
Stop and ask yourself if you think a stock with those kinds of metrics is likely to head higher or lower from here? 🤔 |
I don't think you need to be a stock analyst to know the answer to that! |
Look at some of these stats I pulled directly from ALBT's recent investor presentation from a few weeks ago: |
|
ALBT also laid out goals to accelerate precision diagnostics related to better, safer future development of genetic-based testing, large-scale lab testing related to immune system functionality, pharmacogenomics, toxicology monitoring and immune wellness maintenance. |
ALBT also divulged a staggering 56% insider ownership of the stock! |
You really can't ask for much more confidence from insiders who know the company best than ownership like that. |
A big wild card for ALBT right now is the recent announcement of their partnership for the "KetoAir device." |
This device was just announced, and we don't have official sales numbers yet. |
ALBT said they partnered with Qi Diagnostics to exclusively distribute the KetoAir in North America, South America, the U.K. and the EU. |
KetoAir is the first breathalyzer on the market that uses an AI nutritionist bundled with the nanosensor-based breathalyzer for ketogenic health management. The KetoAir breathalyzer measures the keto status and logs the diet records in the KetoAir app. At the same time, the AI nutritionist analyzes the dietary plan and acts as a companion consultant by providing personalized nutritional and exercise recommendations to help achieve the person's ultimate health goal. |
It's a pretty fascinating development if you ask me and could provide more great upside if they are successful in selling this. |
ALBT also just updated investors on their plans moving forward. |
They said, "Our goal is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. By targeting laboratories with strong financial track records and niche-market advantages, we believe we can effectively leverage LSM's experience and infrastructure to achieve significant synergies with respect to revenue growth and market share." |
I love companies with a "roll-up strategy." |
This is where you find a sector that has a lot of small competitors, and you acquire them to build a much larger company that trades at a significant premium to where the individual companies would trade. |
When you buy private companies and roll them up into a publicly traded stock, it just makes sense that the stock would trade at a much higher multiple than what they acquired. |
At the end of the day, I love the acquisition model that ALBT is pursuing. I think the new products they have introduced have strong market potential. Even if they fumble the ball a little on their rollout, the stock just makes no sense to me at these prices, and best-case scenario, we could see a home run from here! |
I really encourage you to take some time today and do your own homework on this stock and see if it makes sense for you. No matter what you do, always make sure you make trades where you have a good gameplan and understand the risks involved. Everything in life and trading is risky, so make sure you know what you are getting yourself into before you ever decide to buy anything. |
ALBT is a commercial-stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is establishing a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit their investor page. |
Have a great day, and I will follow up with you on this idea very soon! |
|
|
P.S. If you're new (or just haven't done it yet), make sure you join our exclusive SMS list. 📲 All you need to do is text the word "RAGE" to (888) 404-5747 to get all of my latest HOT STOCK ideas and access to live trading events! |
*This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer. | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. |
|
|
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. |
|
|
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. |
|
|
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
If you have a current active subscription with Jason Bond Picks you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at JasonBondPicks.com. |
|
|
In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. |
|
|
|
Post a Comment
Post a Comment